- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Glycogen Hepatopathy in United States
Total 131 results
-
Dompé Farmaceutici S.p.AActive, not recruitingNeurotrophic Keratitis | Corneal Ulcer | Neurotrophic KeratopathyUnited States
-
PepsiCo Global R&DCompletedMuscle Soreness | Muscle Recovery | Glycogen DepletionUnited States
-
Serhat Gumrukcu, MD PhDFrida Therapeutics LLCRecruiting
-
Duke UniversityCompleted
-
Duke UniversityGenzyme, a Sanofi CompanyCompleted
-
Duke UniversityCompletedPompe DiseaseUnited States
-
Duke UniversityCompleted
-
Dwight Koeberl, M.D., Ph.D.Completed
-
Asklepios Biopharmaceutical, Inc.Active, not recruiting
-
BioMarin PharmaceuticalTerminatedLate-onset Pompe DiseaseUnited States, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)United States, Netherlands, United Kingdom, Germany
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase DeficiencyUnited States, Canada, Australia
-
Duke UniversityGenzyme, a Sanofi CompanyActive, not recruitingPompe Disease (Late-onset) | Pompe Disease | GAA DeficiencyUnited States
-
Duke UniversityWithdrawnPompe Disease (Late-onset)United States
-
University of FloridaCompleted
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
Spark TherapeuticsActive, not recruitingLysosomal Storage Diseases | Glycogen Storage Disease Type II | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase DeficiencyUnited States, Canada, Netherlands, France, Denmark, Germany, Italy, United Kingdom
-
Duke UniversityCompleted
-
Duke UniversityCompleted
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II;Pompe's DiseaseCzechia, Taiwan, Belgium, Germany, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, Denmark, France, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Switzerland, Turk... and more
-
Cornea Research Foundation of AmericaCompletedFuchs' Endothelial Dystrophy | Bullous KeratopathyUnited States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, Taiwan, Israel, United Kingdom, France
-
Genzyme, a Sanofi CompanyRecruitingPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Glycogenesis 2 Acid Maltase DeficiencyCroatia, United States, Italy, Belgium, Czechia
-
University of California, San DiegoRocket Pharmaceuticals Inc.Recruiting
-
Genzyme, a Sanofi CompanyTerminatedGlycogenosis 2 | Glycogen Storage Disease Type II (GSD II) | Acid Maltase Deficiency | Pompe Disease (Infantile-Onset)United States, Taiwan, Germany
-
Amicus TherapeuticsRecruitingPompe DiseaseUnited States
-
Vitaflo International, LtdUniversity College London Hospitals; University Medical Center Groningen; University... and other collaboratorsCompletedGlycogen Storage DiseaseUnited States, United Kingdom, France, Netherlands
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2United States, France, Netherlands
-
Astellas Gene TherapiesRecruitingPompe Disease (Late-onset)United States, United Kingdom
-
BioMarin PharmaceuticalCompletedPompe DiseaseUnited States, United Kingdom, France, Australia, Germany
-
SanofiRecruitingGlycogen Storage Disease Type IIBelgium, United States, Italy, Spain, Taiwan, United Kingdom, Netherlands, France, Germany
-
Amicus TherapeuticsAvailablePompe Disease Infantile-OnsetTaiwan, United States, Italy
-
BioMarin PharmaceuticalTerminatedPompe DiseaseUnited States, United Kingdom, Australia, France, Germany, New Zealand
-
Amicus TherapeuticsCompletedGlycogen Storage Disease Type II | Pompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, France, Netherlands
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompleted
-
EmmecellActive, not recruitingEndothelial Dysfunction | Corneal Edema | Fuchs Dystrophy | Corneal Endothelial Dystrophy | Bullous Keratopathy | Pseudophakic Bullous Keratopathy | Corneal Endothelial Dysfunction | Fuchs Endothelial Corneal Dystrophy | Moderate Corneal Endothelial DecompensationUnited States
-
Price Vision GroupCompletedBullous Keratopathy | Fuchs' DystrophyUnited States, Germany
-
University of California, IrvineCompletedMuscle Weakness | Pompe DiseaseUnited States
-
Rocket Pharmaceuticals Inc.Active, not recruitingDanon DiseaseUnited States
-
Rocket Pharmaceuticals Inc.RecruitingDanon DiseaseUnited States
-
Oregon Health and Science UniversityNational Eye Institute (NEI)Recruiting
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)United States, France, Canada, Netherlands, Australia
-
SanofiRecruitingGlycogen Storage Disease Type IIBelgium, United States, China, Germany, Italy, Netherlands, Spain, Taiwan, United Kingdom
-
University of FloridaDiabetes SentryTerminatedClinical Evaluation of a Non-Invasive Hypoglycemia Detector in a Glycogen Storage Disease PopulationGlycogen Storage DiseaseUnited States
-
Duke UniversityGenzyme, a Sanofi CompanyRecruitingLate-Onset Pompe Disease | Lysosomal DiseaseUnited States
-
Rocket Pharmaceuticals Inc.Recruiting
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States